Olverembatinib clinical trials
Also written HQP1351.
How each study uses olverembatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the olverembatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2022 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 5 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 19
Ascentage Pharma Group Inc. (9) · Institute of Hematology & Blood Diseases Hospital, China (7) · M.D. Anderson Cancer Center (3) · The First Affiliated Hospital of Soochow University (3) · First Affiliated Hospital of Zhejiang University (1) · Nanfang Hospital, Southern Medical University (1) · Xijing Hospital (1) · Chen Suning (1)
Often tested with
Tested in the same studies.
Lisaftoclax (1) · Dexamethasone (1) · Allogeneic Anti-CD19 T-cells ThisCART19A (1) · Chimeric Antigen Receptor T-cells (1) · Venetoclax (1) · Azacitidine (1) · Prednisone (1) · Blinatumomab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test olverembatinib, phase 3 first.
- Mar 2027A Study of Olverembatinib in SDH-deficient GIST.Phase 3 · Ascentage Pharma Group Inc.
- Nov 2026Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaPhase 1/2 · Xijing Hospital
- Dec 2026Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLPhase 1/2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLPhase 1 · Institute of Hematology & Blood Diseases Hospital, China
- Jan 2027A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaPhase 1 · M.D. Anderson Cancer Center
- Mar 2027Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or AsciminibPhase 2 · M.D. Anderson Cancer Center
- Oct 2027Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALLPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
Studies
Open first, then newest update. How each study uses olverembatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)Not yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07178912Written as olverembatinib
- Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or AsciminibRecruitingPhase 2M.D. Anderson Cancer CenterNCT06817720Written as olverembatinib
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07840976Written as olverembatinib
- A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06401603Written as Olverembatinib
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT05495035Written as Olverembatinib, APG-2575, Dexamethasone
- A Study of Olverembatinib in SDH-deficient GIST.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06640361Written as Olverembatinib
- Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.RecruitingEarly Phase 1The First Affiliated Hospital of Soochow UniversityNCT07074496Written as Olverembatinib
- A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)RecruitingPhase 3Ascentage Pharma Group Inc.NCT06051409Written as Olverembatinib
- A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingPhase 1Ascentage Pharma Group Inc.NCT03594422Written as HQP1351
- Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07443488Written as Olverembatinib+INO
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06481228Written as Olverembatinib
- Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentRecruitingPhase 1Ascentage Pharma Group Inc.NCT07282093Written as Olverembatinib 20mg
- Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07152041Written as olverembatinib
- Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLRecruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06757855Written as Olverembatinib
- Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06754267Written as Olverembatinib
- A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT06220487Written as Prednisone, Olverembatinib, Blinatumomab, Chidamide
- Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaRecruitingPhase 1/2Xijing HospitalNCT06082934Written as Olverembatinib plus venetoclax and dexamethasone
- A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALLNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT05931757Written as Olverembatinib
- Olverembatinib for FGFR1-rearranged NeoplasmsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT05521204Written as Olverembatinib
- Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05594784Written as Olverembatinib
See all 28 studies that test olverembatinib →
Given beside what is tested · 4 — olverembatinib is usual care or a partner of the new treatment
- Study of Olverembatinib (HQP1351) in Patients With CML-CPRecruitingPhase 3Ascentage Pharma Group Inc.NCT06423911Written as olverembatinib
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07493161Written as Olverembatinib
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07454226Written as Olverembatinib
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT04501120Written as olverembatinib
Codes
What other systems call olverembatinib · ClinicalTrials.gg INT006263
- MeSH (NLM) C579813olverembatinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KV1M7Q3CBPOLVEREMBATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q123846205olverembatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C165549OlverembatinibOne source FDA
- DrugBank DB16185One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C579813 | olverembatinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KV1M7Q3CBP | OLVEREMBATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123846205 | olverembatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C165549 | Olverembatinib | One source FDA |
| DrugBank | DB16185 | — | One source Wikidata |
Also registered as olverembatinib dimesylate (UNII NPJ9AW8AZR).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.